Betaine for Heart Failure
Trial Summary
The trial does not specify if you need to stop taking your current medications, but you cannot use betaine or S-adenosylmethionine supplements during the study. If you are using injectable insulin or oral corticosteroids, you may not be eligible to participate.
Betaine (trimethyglycine) is unique for heart failure treatment as it is not commonly used for this condition, unlike trimetazidine, which is known for its antioxidant properties and ability to improve cardiac metabolism. Betaine's potential benefits in heart failure may relate to its role in cellular metabolism and methylation processes, which are different from the mechanisms of standard heart failure drugs.
12345Eligibility Criteria
This trial is for adults aged 18-75 with non-alcoholic fatty liver disease, elevated ALT levels (a liver enzyme), and normal platelet counts. They must not have severe liver or kidney issues. Group 1 specifically includes diabetic patients with high fasting blood sugar or HgA1c levels.Inclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 4 grams of betaine per day for the first 4 weeks, followed by randomization to either continue 4 grams or increase to 8 grams per day for an additional 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Participant Groups
Betaine (trimethyglycine) is already approved in European Union, United States for the following indications:
- Homocystinuria
- Homocystinuria